Literature DB >> 26183692

Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications.

Roger L Albin1,2,3,4, Amanda Fisher-Hubbard5, Krithika Shanmugasundaram2, Robert A Koeppe6, James F Burke1,2,3, Sandra Camelo-Piragua5, Andrew P Lieberman5, Bruno Giordani7, Kirk A Frey2,6.   

Abstract

Clinical classification of early dementia and mild cognitive impairment (MCI) is imprecise. We reported previously that molecular imaging classification of early dementia and MCI with dual amyloid and dopamine terminal positron emission tomography differs significantly from expert clinical classification. We now report pathological diagnoses in a substantial subset of our previously imaged subjects. Among 36 subjects coming to autopsy, imaging classifications and pathological diagnosis were concordant in 33 cases (κ = 0.85). This approach enhanced specificity of Alzheimer's disease diagnosis. The strong concordance of imaging-based classifications and pathological diagnoses suggests that this imaging approach will be useful in establishing more accurate and convenient classification biomarkers for dementia research.
© 2015 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26183692      PMCID: PMC4836870          DOI: 10.1002/ana.24481

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment.

Authors:  Roger L Albin; Robert A Koeppe; James F Burke; Bruno Giordani; Michael R Kilbourn; Sid Gilman; Kirk A Frey
Journal:  Arch Neurol       Date:  2010-04

2.  Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.

Authors:  Masahiro Maruyama; Hitoshi Shimada; Tetsuya Suhara; Hitoshi Shinotoh; Bin Ji; Jun Maeda; Ming-Rong Zhang; John Q Trojanowski; Virginia M-Y Lee; Maiko Ono; Kazuto Masamoto; Harumasa Takano; Naruhiko Sahara; Nobuhisa Iwata; Nobuyuki Okamura; Shozo Furumoto; Yukitsuka Kudo; Qing Chang; Takaomi C Saido; Akihiko Takashima; Jada Lewis; Ming-Kuei Jang; Ichio Aoki; Hiroshi Ito; Makoto Higuchi
Journal:  Neuron       Date:  2013-09-18       Impact factor: 17.173

3.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

4.  Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.

Authors:  James F Burke; Roger L Albin; Robert A Koeppe; Bruno Giordani; Michael R Kilbourn; Sid Gilman; Kirk A Frey
Journal:  Brain       Date:  2011-05-09       Impact factor: 13.501

5.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

6.  Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.

Authors:  Gil D Rabinovici; William J Jagust; Ansgar J Furst; Jennifer M Ogar; Caroline A Racine; Elizabeth C Mormino; James P O'Neil; Rayhan A Lal; Nina F Dronkers; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  Ann Neurol       Date:  2008-10       Impact factor: 10.422

Review 7.  Frontotemporal lobar degeneration: a clinical approach.

Authors:  Elissaios Karageorgiou; Bruce L Miller
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

8.  Accuracy of the clinical evaluation for frontotemporal dementia.

Authors:  Mario F Mendez; Jill S Shapira; Aaron McMurtray; Eliot Licht; Bruce L Miller
Journal:  Arch Neurol       Date:  2007-06

9.  Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.

Authors:  Roger L Albin; James F Burke; Robert A Koeppe; Bruno Giordani; Sid Gilman; Kirk A Frey
Journal:  J Nucl Med       Date:  2013-04-09       Impact factor: 10.057

10.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update.

Authors:  Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2009-11-19       Impact factor: 17.088

View more
  3 in total

Review 1.  Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-14       Impact factor: 5.081

2.  Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia.

Authors:  Thomas G Beach; Charles H Adler; Nan Zhang; Geidy E Serrano; Lucia I Sue; Erika Driver-Dunckley; Shayamal H Mehta; Edouard E Zamrini; Marwan N Sabbagh; Holly A Shill; Christine M Belden; David R Shprecher; Richard J Caselli; Eric M Reiman; Kathryn J Davis; Kathy E Long; Lisa R Nicholson; Anthony J Intorcia; Michael J Glass; Jessica E Walker; Michael M Callan; Javon C Oliver; Richard Arce; Richard C Gerkin
Journal:  PLoS One       Date:  2020-04-22       Impact factor: 3.240

Review 3.  Neuroimaging in Lewy body dementia.

Authors:  Tayyabah Yousaf; George Dervenoulas; Polytimi-Eleni Valkimadi; Marios Politis
Journal:  J Neurol       Date:  2018-05-14       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.